It is frequently associated with the metabolic syndrome (MS) Non

It is frequently associated with the metabolic syndrome (MS). Nonalcoholic fatty liver disease can progress to cirrhosis and/or carcinoma hepatocellular (HCC). The objectives of this study are to compare the presentation, treatments, evolution

of HCC regardless of the underlying liver disease, whether viral, alcohol-related or related to metabolic syndrome as the only factor risk. Methods: From 01/2005 to Selleck Cisplatin 12/2012, 452 patients meeting these criteria were admitted to our unit for the management of HCC (Virus n = 196, Alcohol n = 173, metabolic syndrome n = 83). Results: Cirrhosis Selleck CHIR-99021 was more frequently associated with viral or alcoholic etiology (p 50 mm (p p = 0.27) probably due to the size of resected tumors in the metabolic syndrome group. Conclusion: HCC associated with metabolic syndrome as the only risk factor are the third cause of primary malignant liver tumors in this series. They have distinct characteristics with a non-cirrhotic liver development and more unique macronodule, which allow more frequently surgical resection. But comorbidities related to the MS and

the large size of lesions involved in relapse, should be taken into account. Response and tolerance

to non-surgical treatments (TACE or Sorafenib) appears similar to other etiologies. Given the frequency of metabolic syndrome in our population, patients at risk should be clearly better defined. Key Word(s): 1. hepatocellular carcinoma nonalcoholic fatty liver disease liver cirrhosis surgical resection TACE Presenting Author: XAVIER ADHOUTE Additional Authors: GUILLAUME PENARANDA, PAUL CASTELLANI, HERVE PERRIER, GAELLE LEFOLGOC, GUILLAUME CONROY, JEAN PIERRE BRONOWICKI, MARC BOURLIERE, JEAN LUC RAOUL Corresponding Author: XAVIER ADHOUTE Affiliations: Alphabio Laboratory, Hôpital Saint-Joseph, Hôpital Saint-Joseph, Hôpital Saint-Joseph, Hôpital De Brabois selleck products Chu Nancy, Hôpital De Brabois Chu Nancy, Hôpital Saint-Joseph, Oncology Objective: HKLC is new staging system with treatment guidelines determined from a large cohort of B virus-related HCC (80%), treated or not, aimed to improve the prognostic classification for HCC, using surgery in subsets of intermediate and advanced HCC (Yau T and al. Gastroenterology 2014; 146). This score includes the following prognostic factors: tumor size, number, vascular invasion, distant metastases, patient performance score (ECOG PS) and liver function.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>